ViroCyt® Continues to Innovate for the Gene Therapy Field
BROOMFIELD, CO–(Marketwired – May 4, 2016) – ViroCyt®, the leader in rapid virus quantification, announced today the release of new member of the ViroTag® portfolio of antibody-based detection reagents: ViroTag AAV5.
Adeno-Associated Virus, or AAV, is a family of 12 different serotypes, and are a major tool in the gene therapy field, with well over 100 clinical trials currently underway. Quantification of these viral vectors, however, is a significant bottleneck in their production. Current methods, such as quantitative polymerase chain reaction (qPCR), are time-consuming and often highly variable, with as much as a 10-fold difference in results for the same sample. In direct response to this unmet need, ViroCyt has created a growing list of virus-specific kits under the ViroTag tradename, that—when used with the Virus Counter 3100—make real-time quantification of viruses such as AAV a reality.
“Having recently launched ViroTag for AAV2 and AAV3, our commitment to the advancement of AAV-based therapies is evident,” stated Robert Kline, ViroCyt President and Chief Executive Officer. “The feedback from the gene therapy community was that amount of research and development focusing on AAV5 merited the investment to develop a reagent for this specific serotype, and we will continue to add to the list of products for this application area.”
The launch of ViroTag AAV5 coincides with this week’s annual meeting of the American Society of Gene and Cell Therapy being held in Washington, DC.
Added Dr. Michael Olszowy, Chief Technology Officer at ViroCyt, “ViroCyt has targeted a critical issue in the gene therapy space: Tracking the amount of viral vector particles during the growth, harvest and purification steps. Because of the potential adverse outcomes of dosing patients with too much vector, understanding particle count in the final formulation is also essential. Viral vector groups now have the ability to accelerate the consistent creation of safe and effective products.”
ViroCyt has developed a novel approach enabling direct, biologically-specific quantification of viruses in minutes rather than the days or weeks required by more traditional methods. Marketed under the tradename ViroTag®, this new product category utilizes a fluorescently-labeled, high-affinity antibody targeted to the virus of interest. During a 1-minute sample analysis, the preparation is evaluated with the Virus Counter® 3100, an instrument developed expressly for the purpose of real-time virus quantification. The growing list of products includes kits to detect Adenovirus, Adeno-Associated Virus, Baculovirus and Influenza.
About ViroCyt, Inc.
ViroCyt, Inc. was created with the goal of bringing game-changing solutions to the Life Science industry. Our primary focus is replacing outdated technologies that slow down the pace of virus-related research and product development. Additional information can be found at http://www.virocyt.com.
Dr. Michael Artinger
Vice President, Marketing & Strategic Partnering
Source: ViroCyt, Inc.